Seelos Therapeutics Stock Forecast, Price & News

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

Is Seelos Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seelos Therapeutics stock.
View analyst ratings for Seelos Therapeutics or view top-rated stocks.

How has Seelos Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SEEL stock has increased by 111.5% and is now trading at $1.65.
View which stocks have been most impacted by COVID-19.

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Seelos Therapeutics.

What price target have analysts set for SEEL?

5 equities research analysts have issued 12 month target prices for Seelos Therapeutics' shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate Seelos Therapeutics' share price to reach $10.20 in the next twelve months. This suggests a possible upside of 518.2% from the stock's current price.
View analysts' price targets for Seelos Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the following people:

• Raj Mehra, Chairman, President & Chief Executive Officer
• Jessica Kardish, Vice President-Clinical Development & Operations
• Michael Golembiewski, Chief Financial Officer
• Lucas Pilipski, Executive Director-Clinical Operations
• Tim Whitaker, Chief Medical Officer

Who are some of Seelos Therapeutics' key competitors?

Some companies that are related to Seelos Therapeutics include Cara Therapeutics (CARA), Emisphere Technologies (EMIS), Oramed Pharmaceuticals (ORMP), Affimed (AFMD), Dyne Therapeutics (DYN), Atea Pharmaceuticals (AVIR), Prelude Therapeutics (PRLD), Janux Therapeutics (JANX), Kronos Bio (KRON), Theravance Biopharma (TBPH), Applied Molecular Transport (AMTI), Annexon (ANNX), Eagle Pharmaceuticals (EGRX), Amryt Pharma (AMYT) and Collegium Pharmaceutical (COLL).
View all of SEEL's competitors.

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Gendell Jeffrey L (1.82%), Two Sigma Advisers LP (1.73%), Geode Capital Management LLC (1.68%), Millennium Management LLC (1.32%) and Two Sigma Investments LP (0.96%).
View institutional ownership trends for Seelos Therapeutics.

Which major investors are selling Seelos Therapeutics stock?

SEEL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Millennium Management LLC, Renaissance Technologies LLC, Deutsche Bank AG, Goldman Sachs Group Inc., California State Teachers Retirement System, and New York State Common Retirement Fund.
View insider buying and selling activity for Seelos Therapeutics or view top insider-selling stocks.

Which major investors are buying Seelos Therapeutics stock?

SEEL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Advisers LP, Vontobel Holding Ltd., Geode Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Penserra Capital Management LLC, Gendell Jeffrey L, and Franklin Resources Inc..
View insider buying and selling activity for Seelos Therapeutics or or view top insider-buying stocks.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $1.65.

How much money does Seelos Therapeutics make?

Seelos Therapeutics has a market capitalization of $168.94 million and generates $380 thousand in revenue each year. The company earns $-19.10 million in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Seelos Therapeutics have?

Seelos Therapeutics employs 10 workers across the globe.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

Where are Seelos Therapeutics' headquarters?

Seelos Therapeutics is headquartered at 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at (646) 293-2100, via email at [email protected], or via fax at 858-436-8155.